Head-to-head · Cost-Efficiency Index
Ondra Health vs REMEVi
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
Ondra Health
Value shoppers who want one of the lowest disclosed prices on both molecules without giving up nationwide access or pharmacy verification.
Visit Ondra HealthREMEVi
Cost-first shoppers who want spanish-speaking patients wanting bilingual, LegitScript-certified compounded GLP-1.
Visit REMEViThe verdict
Ondra Health takes it, leading the Cost-Efficiency Index 90 to 80. A rare combination — near-rock-bottom pricing on both molecules, all-50 access, brand-name availability, and a LegitScript-verified pharmacy behind it. REMEVi still earns a B− — Cost-first shoppers who want spanish-speaking patients wanting bilingual, LegitScript-certified compounded GLP-1.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the board). See how it stacks up: CoreAge Rx vs Ondra Health.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | Ondra Health | REMEVi |
|---|---|---|
| Cost-Efficiency Index | 90/100 | 80/100 |
| Semaglutide / mo | $93/mo | $219/mo |
| Tirzepatide / mo | $166/mo | $319/mo |
| Semaglutide / yr (modeled) | $1,116 | $2,628 |
| Tirzepatide / yr (modeled) | $1,992 | $3,828 |
| Coverage | All 50 states | All 50 states |
| Oral / sublingual | No | Yes |
| Brand-name access | Yes | Compounded only |
| Rank on the board | #2 | #37 |
Ondra Health
90/100Where the value is
- Among the lowest disclosed prices on the board — $93 semaglutide and $166 tirzepatide
- Available in all 50 states with both molecules published for clean cost modeling
- LegitScript-certified, and offers FDA-approved brand-name access alongside compounded
The tradeoffs
- A newer, lower-profile operator without CoreAge's long flat-price track record
- No oral/sublingual route
REMEVi
80/100Where the value is
- A genuinely flat rate: 'the same price at every dose', stated as such, with no dose upcharge and no introductory rate to step off
- Longer terms are published openly rather than used as a teaser — semaglutide falls to $189 on 12 weeks and $149 on 52
- A daily oral semaglutide tablet is offered alongside the injection
The tradeoffs
- The flat rate is the highest entry price of the top-scoring programmes here; the cheaper $149 figure needs a full year
- No FDA-approved brand-name pathway — the Wegovy and Ozempic pages are comparison content, not products
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.